• Skip to primary navigation
  • Skip to main content

Convergence Healthcare Advisors

Bulge Bracket Expertise, Boutique Bank Environment

  • Home
  • Team
  • Services
  • Experience
  • News
  • Contact
You are here: Home / Transactions / Sale of Dascena Labs to CirrusDx

Dascena Labs

Sale of Dascena Labs

CirrusDx

Terms: Not Disclosed
Date Announced: August 2022

CirrusDx Acquires Dascena’s Texas Laboratory Business, Expanding Infectious Disease Portfolio
ROCKVILLE, Md., Aug. 3, 2022 /PRNewswire/ — Cirrus Dx, Inc. (“CirrusDx”), an infectious disease diagnostics and laboratory company, announces the acquisition of Dascena Inc.’s Houston-based laboratory business, Dascena Labs, LLC (“Dascena Labs”).
Through the acquisition CirrusDx will enhance its current services by further expanding its national laboratory footprint, while strengthening its sequencing capabilities. Dascena Labs is a state-of-the-art CLIA laboratory capable of high-volume specialized testing.
“We are pleased to continue to drive growth” said Kyle Armantrout, Managing Partner at CirrusDx. “Acquiring the expertise and technology of Dascena Labs aligns with our services, allowing us to build on our current offerings and our mission to support long-term care centers, regional hospitals, and healthcare providers.”

The principals of Convergence Healthcare Advisors LLC and Seven Hills Healthcare Advisors LLC are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer. Member FINRA/SIPC. 4151 N. Mulberry Drive, Suite 252 Kansas City, MO 64116.

© 2023 Convergence Healthcare Advisors · Built on the Genesis Framework by AMN Design · Powered by WordPress

Legal Disclosures